Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

MDPI

Monoclonal Antibodies, Gene Silencing and Gene Editing (CRISPR) Therapies for the Treatment of Hyperlipidemia—The Future Is Here -

Hyperlipidemia is a significant risk factor for atherosclerotic cardiovascular disease. Undertreatment of elevated lipids persists despite existing therapies. Here, we provide an update on

1620247546080948224

Jamal Rana, MD

Future is here! Treatment of Hyperlipidemia #CRISPR , Gene Silencing & Monoclonal Antibodies Our exciting review led by Dr. Hermel with Dr. Lieberman, @CardioMDPhD & @virani_md Full text: https://t.co/euVlQysLuV https://t.co/euVlQysLuV https://t.co/euVlQysLuV - view on twitter

More coverage: #CRISPR

Read the full article here

See more from Jamal Rana, MD